SINGAPORE--(BUSINESS WIRE)--QuintilesIMS today was named Asia Pacific Contract Research Organization (CRO) Company of the Year by Frost & Sullivan, a leading business research and consulting firm, because of its industry leadership and service delivery excellence. The evaluation used in Frost & Sullivan’s selection was conducted before Quintiles and IMS Health merged earlier this month.
“The QuintilesIMS merger is another milestone in Quintiles’ history of leadership and innovation,” said Rhenu Bhuller, Partner, Transformational Health, Frost & Sullivan. “Biopharma and medtech companies are eager for innovative solutions to the complex challenges they face – especially for evidence supporting outcomes - and value-based care. QuintilesIMS is well-aligned to provide those solutions."
The Frost & Sullivan Company of the Year Award evaluates CROs on visionary innovation and performance as well as customer impact. QuintilesIMS ranked highly in these categories, in particular for pioneering new and complex areas such as regenerative and personalized medicine. With this most recent honor, Quintiles, now QuintilesIMS, has won the F&S CRO Company of the Year award eight times in 10 years.
QuintilesIMS Asia Pacific President Anand Tharmaratnam said: “This award belongs to our dedicated employees, and I believe Asia Pac will be a global leader in 21st century healthcare innovation. I’m excited about the new solutions QuintilesIMS can offer by connecting clinical to commercial to real-world patient outcomes. We are eager to lead Asia Pac’s transformation to become a center for healthcare innovation.”
With a database of 18,500+ investigator sites or hospitals across Asia Pacific, QuintilesIMS has conducted more than 1,250 studies covering a wide range of therapeutic areas – including cardiovascular disease, oncology, neurology and infectious diseases – involving 273,000 patients since 2000.
Over the last 12 months QuintilesIMS (formed by the recent merger of Quintiles and IMS Health) has been named to Fortune magazine’s “World’s Most Admired Companies” list for the second consecutive year; recognized by the Ethisphere Institute as a 2016 World’s Most Ethical Company®; and named the industry leader in Phase I, Phase II/III and Phase IV services by Industry Standard Research’s 2016 CRO Quality Benchmarking reports, among other honors.
QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles and IMS Health, QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes and enhanced clinical trial outsourcing through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial bringing clients a unique opportunity to realize the full potential of innovations and advance healthcare outcomes.
As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders for the development and approval of new therapies, identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. To learn more, visit www.QuintilesIMS.com.